Rani Therapeutics (NASDAQ:RANI – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01, Zacks reports.
Rani Therapeutics Stock Performance
Shares of NASDAQ RANI traded up $0.03 during trading hours on Monday, hitting $0.57. 361,050 shares of the stock were exchanged, compared to its average volume of 889,765. The company’s fifty day simple moving average is $0.74 and its two-hundred day simple moving average is $0.92. The company has a market cap of $80.05 million, a PE ratio of -2.13 and a beta of 0.61. Rani Therapeutics has a 1-year low of $0.51 and a 1-year high of $2.15.
Analyst Ratings Changes
A number of research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating on shares of Rani Therapeutics in a report on Thursday, October 22nd. Weiss Ratings upgraded shares of Rani Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 30th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Rani Therapeutics in a research report on Tuesday, October 6th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.33.
Check Out Our Latest Research Report on RANI
About Rani Therapeutics
Rani Therapeutics Holdings, Inc is a clinical-stage biotherapeutics company developing technology designed to deliver biologic medicines orally. Its proprietary RaniPill platform is an ingestible robotic capsule intended to transport biologic drugs through the stomach and release them into the small intestine, where they can be absorbed into the bloodstream. The approach is intended to address the limitations of many biologic therapies, which are commonly administered by injection or infusion.
The company is advancing the RaniPill platform for potential use with a range of large-molecule medicines, including peptides, proteins and antibodies.
Recommended Stories
- Five stocks we like better than Rani Therapeutics
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Rani Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rani Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
